1018-00009 · Client 1018 · Strategy

economic-substance-analysis-memo.docx DOCUMENT M&A / Corporate

155 / 176 ← → ✕

RESEARCH MEMORANDUM PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

TO: Leonard Cross, Responsible Partner Garrett Simmons, Lead Associate

FROM: Leila Nazari, Working Associate

DATE: August 18, 2022

RE: Economic Substance Doctrine and DEMPE Functions Analysis — Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination Defense (TY 2017–2020)

MATTER NO.: 1018-00009

CLIENT: Penterra Pharmaceuticals Corp.

This memorandum is protected by the attorney-client privilege and constitutes attorney work product prepared in anticipation of litigation. It is intended solely for the use of the individuals to whom it is addressed and should not be disclosed, distributed, or copied without the express prior authorization of the responsible partner. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the economic substance doctrine as applied in the transfer pricing context and the DEMPE framework — encompassing the functions of Development, Enhancement, Maintenance, Protection, and Exploitation — under the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as revised in 2022), with specific application to the IRS's anticipated challenge to Penterra Biopharma International DAC ("PBI") as a qualified participant in the cost-sharing arrangement ("CSA") with Penterra Pharmaceuticals Corp. ("PPC").

The IRS Large Business & International Division ("LB&I") has opened an examination of PPC's tax years 2017 through 2020, assigned Exam Team ID LB&I-NE-TP-2022-00641 and initiated on May 16, 2022. Based on preliminary Information Document Requests ("IDRs") and the scope of the examination as communicated during the opening conference, the IRS has indicated that it may challenge PBI's economic substance as an intellectual property owner and CSA participant, asserting that key DEMPE functions remained in the United States — principally at PPC's headquarters in Princeton Junction, New Jersey. If the IRS sustains this challenge, it could serve as the basis for proposed adjustments to PBI's cost-sharing ratios and royalty rates, potentially reallocating significant income from PBI to PPC for U.S. federal income tax purposes. Additionally, if the IRS frames its challenge under the economic substance doctrine codified at IRC § 7701(o), rather than — or in addition to — a straightforward § 482 arm's-length pricing adjustment, PPC could face strict-liability penalties under IRC § 6662(b)(6) without the benefit of a reasonable-cause defense predicated on contemporaneous transfer pricing documentation.

Conclusion. Based on the analysis set forth below, it is my assessment that PBI possesses sufficient economic substance to justify its role as IP owner and CSA participant for the non-Americas territory. This conclusion is supported by PBI's substantial and growing headcount (185 employees by 2020), its independent decision-making authority exercised by a Dublin-based management team led by Managing Director Aidan Naughton, its significant capital commitments under the CSA (including aggregate annual cost-sharing payments ranging from $186.15 million to $255.52 million during the exam period and a platform contribution transaction payment of $312 million), and its performance of meaningful DEMPE functions in Ireland. PBI is not a passive "cash box" or shell entity. It operates an active commercial enterprise responsible for the regulatory, commercial, and supply-chain management of PPC's pharmaceutical products across 68 non-Americas country markets. The economic substance doctrine, properly applied under § 7701(o) and the supporting body of case law, does not support recharacterization of PBI's role.

This memorandum proceeds as follows: Section II sets forth the relevant background facts. Section III provides the legal framework governing the economic substance doctrine, including its codification, common law origins, interaction with IRC § 482, key case law, and penalty implications. Section IV analyzes the DEMPE framework under the OECD Transfer Pricing Guidelines. Section V applies the legal framework to PBI's specific facts. Section VI offers strategic recommendations for PPC's defense. Section VII provides overall conclusions. Supporting appendices summarize PBI's DEMPE functions, the relevant statutory and regulatory authorities, and key case law.

II. Background Facts Relevant to the Analysis

The following factual summary is based on a review of corporate organizational documents, intercompany agreements, PBI board minutes, PPC and PBI financial statements, the CSA and amendments thereto, PBI human-resources records, regulatory filing documentation, and discussions with PPC's in-house tax department (Vice President of Tax, Margaret Reyes). This summary will be supplemented as additional documentation is gathered through the IDR process and in coordination with PBI's Irish counsel, Thornbury & Keogh.

A. Corporate Structure

Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC's headquarters are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is the ultimate parent of a multinational group that discovers, develops, manufactures, and commercializes pharmaceutical products globally. As of 2020, PPC employed approximately 14,500 employees worldwide and reported consolidated global revenues in excess of $7.8 billion.

PPC's international structure relevant to this analysis is as follows:

PPC owns 100% of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg. PHL's registered office is located at 14, rue Aldringen, L-1118 Luxembourg. For U.S. federal income tax purposes, PHL has elected to be treated as a disregarded entity under Treas. Reg. § 301.7701-3 (check-the-box election effective as of PHL's date of formation). Accordingly, for U.S. tax purposes, PPC is treated as the direct owner of PHL's subsidiary.

PHL owns 100% of Penterra Biopharma International DAC ("PBI"), a Designated Activity Company organized under the laws of Ireland. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish tax reference number is 3218764T. PBI serves as the principal entity for the commercialization and exploitation of PPC's pharmaceutical intellectual property in all territories outside the Americas (i.e., excluding North America, Central America, South America, and the Caribbean).

Additionally, Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company with its registered office and manufacturing facility located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland (Companies Registration Office Number 512347). PMI operates as a contract manufacturer for PBI, producing pharmaceutical products for the non-Americas markets under a contract manufacturing agreement at a cost-plus markup of 8%. PMI employs approximately 620 employees at its Cork facility and operates under good manufacturing practice ("GMP") standards as required by the European Medicines Agency ("EMA"), the Irish Health Products Regulatory Authority ("HPRA"), and the applicable regulatory authorities in PBI's distribution markets. PMI's contract manufacturing arrangement with PBI is a separate intercompany agreement that is also within the scope of the IRS examination, though the primary focus of this memorandum is on PBI's role as IP owner and CSA participant.

B. The Cost-Sharing Arrangement and IP Structure

PBI was incorporated on March 15, 2012. The CSA between PPC and PBI was executed and became effective on July 1, 2012. The CSA was structured as a qualified cost-sharing arrangement ("QCSA") within the meaning of Treas. Reg. § 1.482-7. Under the CSA, PBI acquired the right to develop and exploit PPC's existing and future pharmaceutical intellectual property outside the Americas in exchange for two categories of consideration:

First, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC. The PCT payment compensated PPC for making its existing pre-CSA intellectual property — including approved and pipeline pharmaceutical compounds, related know-how, clinical trial data, and regulatory filings — available to PBI for development and exploitation in the non-Americas territory. The PCT payment was determined using a discounted cash flow methodology based on projected income streams from the non-Americas territory. We note that the IRS and PPC's economic advisors have differed on the appropriate weighted average cost of capital ("WACC") applied in the PCT valuation: the IRS has indicated a preliminary position that a 7.2% WACC is appropriate, while Whitmore Valuation Group LLC (PPC's retained economic expert) has applied a 9.8% WACC. This valuation dispute is addressed separately in Dr. Helena Vasquez's expert analysis and is not the primary focus of this memorandum, though the PCT valuation methodology and any associated adjustments may interact with the substance analysis discussed herein.

Second, under the CSA, PBI makes ongoing annual cost-sharing payments to PPC in proportion to PBI's reasonably anticipated benefits ("RAB") from the intangible development activities funded through the arrangement. The cost-sharing percentages and absolute payment amounts for the examination years are as follows:

The gradual increase in PBI's cost-sharing percentage over the examination period reflects the growing proportional share of reasonably anticipated benefits attributable to PBI's non-Americas territory, driven by expanding market penetration, regulatory approvals in additional jurisdictions, and favorable revenue trends in PBI's markets relative to the Americas.

In addition to the CSA, PBI maintains a legacy IP royalty arrangement under which PBI licenses certain pre-2012 compounds from PPC at a royalty rate of 4.5% of net sales for the non-Americas territory. This royalty covers compounds that were fully developed and commercialized prior to the CSA effective date and were not included in the PCT calculation.

PPC's product portfolio includes three key products with significant global and non-Americas revenue:

• Veritaxol (oncology): Global net sales of $3.12 billion (2020), of which $1.34 billion was attributable to non-Americas markets (PBI territory).

• Imvara (immunology): Global net sales of $1.87 billion (2020), of which $0.79 billion was attributable to non-Americas markets.

• Cerulon (rare disease): Global net sales of $0.62 billion (2020), of which $0.28 billion was attributable to non-Americas markets.

These three products collectively accounted for approximately $2.41 billion in non-Americas net sales in 2020, representing the majority of PBI's revenue base. PBI also commercializes additional products in the PPC portfolio across its territory, contributing to PBI's total FY 2020 revenue of €2.14 billion.

C. PBI's Operations and Substance in Ireland

PBI has maintained and expanded a meaningful operational presence in Ireland since its incorporation in 2012. The following facts are drawn from PBI's human-resources records, organizational charts, financial statements, real-property leases, board meeting records, and regulatory filing documentation.

Headcount and Personnel. PBI's headcount has grown organically from 52 employees at the time of its establishment in 2012 to 185 employees by the end of fiscal year 2020. PBI's Managing Director is Aidan Naughton, who is based in Dublin and reports to PBI's board of directors. Mr. Naughton has served as Managing Director since 2013 and exercises day-to-day authority over PBI's commercial, regulatory, and operational functions. PBI's Dublin-based workforce includes personnel in the following functional areas: regulatory affairs, medical affairs, commercial strategy, supply-chain management, finance, legal, human resources, and information technology. PBI's employees are not mere nominal appointees; they occupy substantive roles with genuine decision-making responsibility over PBI's commercial operations in the non-Americas territory.

Functional Activities. PBI's core functions include: (a) regulatory affairs — preparation, submission, and management of marketing authorization applications and variations across 68 non-Americas country markets, including submissions to the EMA, the HPRA, the UK Medicines and Healthcare products Regulatory Agency ("MHRA"), and numerous national regulatory agencies; (b) medical affairs — management of post-marketing surveillance, adverse event reporting, and medical information inquiries for the non-Americas territory; (c) commercial strategy — development and execution of pricing strategies, reimbursement negotiations with government payers and private insurers, market-access initiatives, and launch planning for new products and new market entries; and (d) supply-chain management — coordination of manufacturing with PMI in Cork, management of logistics and distribution to non-Americas markets, inventory planning, and quality assurance oversight of the non-Americas supply chain.

Commercial Decision-Making. PBI bears market risk for the non-Americas territory and makes key commercial decisions independently of PPC. Specifically, PBI exercises independent authority over pricing across 68 country markets, market entry decisions (including the sequencing and prioritization of new country launches), and the selection and management of distribution partners in markets where PBI does not maintain a direct sales presence. PBI's pricing decisions are documented in internal pricing committee meeting records, which reflect market-specific analysis of competitive dynamics, regulatory requirements, payer negotiations, and profitability targets. PPC does not dictate PBI's pricing or market-entry decisions, though PPC exercises normal oversight as the ultimate parent in a multinational group.

Office Space. PBI occupies approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, under a long-term lease. The office houses PBI's management team, regulatory affairs department, commercial strategy group, supply-chain coordination function, and administrative support staff.

Board Governance. PBI's board of directors convenes quarterly meetings in Dublin. Over the examination period (TY 2017–2020), PBI held a total of 42 board meetings, including regularly scheduled quarterly meetings and special sessions convened to address significant commercial and regulatory matters. All 42 meetings were held in Dublin. The board meetings are documented through formal agendas and minutes, which reflect substantive discussion and deliberation on matters including: annual budgets and financial performance, cost-sharing calculations, regulatory strategy, commercial performance by product and by market, capital expenditure approvals, supply-chain matters, and risk management. The board minutes will be a critical category of evidence in demonstrating PBI's independent decision-making authority and governance integrity.

Regulatory Expenditures. During the examination period (2017–2020), PBI incurred cumulative regulatory expenditures of €47.2 million related to regulatory submissions, marketing authorization applications, post-marketing commitments, and regulatory compliance across 68 non-Americas country markets. These expenditures represent capital investments in the regulatory infrastructure necessary to commercialize PPC's products outside the Americas and constitute a meaningful contribution to the Development, Enhancement, and Maintenance of the underlying pharmaceutical IP.

Banking and Financial Independence. PBI maintains an independent banking relationship with Glenmore Bank Ireland plc. PBI operates its own treasury function and manages its own cash flows, including collections from non-Americas customers, payments to PMI under the contract manufacturing arrangement, cost-sharing payments to PPC under the CSA, and royalty payments to PPC under the legacy IP license.

Financial Profile. PBI's fiscal year 2020 financial results reflect a substantial commercial enterprise: total revenue of €2.14 billion and pre-tax income of €1.06 billion. PBI's Irish effective tax rate on trading income is 12.5%. Beginning in fiscal year 2016, PBI claimed relief under Ireland's Knowledge Development box ("KDB"), which provides a reduced effective tax rate of 6.25% on qualifying income derived from qualifying assets (as defined by Irish Finance Act 2015, section 769R), which in PBI's case includes income attributable to IP developed through PBI's co-funded R&D activities under the CSA. The availability and application of the KDB relief is a matter of Irish tax law and does not directly affect the U.S. federal income tax analysis, though the IRS may reference PBI's effective tax rate in framing its broader challenge to the arrangement.

D. IRS Position (Anticipated)

Based on the opening conference, the scope and content of IDRs issued to date, and informal communications between PPC's in-house tax department and the examination team, the IRS has signaled that it may advance the following position:

The IRS asserts, in part, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. Specifically, the IRS argues that the key DEMPE functions associated with PPC's pharmaceutical IP — principally the conduct of research and development activities and certain strategic management functions — remained in the United States at PPC's headquarters in Princeton Junction, New Jersey. Under this theory, PBI is characterized as primarily a funding entity that co-funded R&D costs through the CSA but did not perform the substantive functions necessary to justify its attribution of IP ownership and the associated income streams.

If sustained, this recharacterization could support the IRS's proposed adjustments in several ways: (a) recharacterization of PBI's CSA cost-sharing payments as something other than arm's-length consideration for a co-development interest, potentially leading to a reallocation of the cost-sharing ratios; (b) adjustment of the royalty rate under the legacy IP license; and (c) in the most aggressive formulation, disregard of PBI's participation in the CSA entirely, treating PPC as the sole owner and developer of the IP and PBI as a mere licensee entitled to routine returns.

The examination team assigned to this matter includes Supervisory Revenue Agent Gerald Meskill, Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and IRS Chief Counsel Attorney-Advisor Franklin Rosario. The involvement of a Chief Counsel attorney from the outset suggests that the IRS views this examination as a significant matter and may be developing legal theories beyond standard § 482 pricing adjustments.

III. Legal Framework: The Economic Substance Doctrine

A. Codification Under IRC § 7701(o)

The economic substance doctrine was codified by the Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, § 1409, 124 Stat. 1029, 1067-70 (2010), which added section 7701(o) to the Internal Revenue Code. Section 7701(o) provides that, in the case of any transaction to which the economic substance doctrine is relevant, such transaction shall be treated as having economic substance only if two conditions are met:

First, the transaction changes in a meaningful way (apart from federal income tax effects) the taxpayer's economic position. This is commonly referred to as the "economic substance" prong or the "objective" prong. The inquiry examines whether the transaction has real economic consequences beyond the generation of tax benefits. In evaluating this prong, courts and the IRS consider whether the transaction generates a meaningful pre-tax profit, involves the commitment of genuine capital at risk, and alters the taxpayer's economic position in a way that would matter absent any tax considerations.

Second, the taxpayer has a substantial purpose (apart from federal income tax effects) for entering into such transaction. This is commonly referred to as the "business purpose" prong or the "subjective" prong. This inquiry examines whether the taxpayer's motivations for entering into the transaction include a genuine non-tax business reason. The existence of a tax benefit does not negate a finding of business purpose so long as the taxpayer also had a substantial non-tax purpose for the transaction.

Critically, § 7701(o) imposes a conjunctive test: both prongs must be satisfied. A transaction that changes the taxpayer's economic position in a meaningful way but lacks a substantial non-tax business purpose will fail the test, as will a transaction that has a substantial non-tax purpose but does not change the taxpayer's economic position in a meaningful way.

Section 7701(o)(5)(C) provides that the determination of whether the economic substance doctrine is "relevant" to a transaction is made in the same manner as if § 7701(o) had never been enacted. This provision preserves the pre-codification analytical framework for determining when the doctrine applies in the first instance, while standardizing the two-prong test that applies once the doctrine is found to be relevant.

Although § 7701(o) is drafted in terms of "transactions," the economic substance analysis has been applied by the IRS and courts to entities and ongoing arrangements, not merely discrete, isolated transactions. In the transfer pricing context, the IRS may invoke the economic substance doctrine to challenge the participation of a foreign entity in intercompany transactions — such as a CSA or IP licensing arrangement — where the IRS contends that the entity lacks the operational substance to be treated as a bona fide participant. Where the entity is viewed as a shell without meaningful economic activity, the IRS may argue that the intercompany arrangement should be disregarded or recharacterized, with the associated income reallocated to the entity that possesses the substance underlying the income-generating functions.

The relevance of the economic substance doctrine to transfer pricing disputes lies in its potential to override the arm's-length analysis. Even where intercompany pricing might satisfy arm's-length standards when tested under the § 482 regulations, the IRS may argue that the entity to which income is attributed under the intercompany pricing structure lacks the economic substance necessary to be treated as the true owner, developer, or exploiter of the relevant intangible property. In effect, the economic substance doctrine functions as a threshold inquiry: before testing whether intercompany pricing is arm's-length, the IRS may first ask whether the participating entities have sufficient substance to be recognized as the parties to the transactions being tested.

B. Common Law Origins and Evolution

The economic substance doctrine has deep roots in the common law of federal taxation, tracing its origins to the Supreme Court's seminal decision in Gregory v. Helvering, 293 U.S. 465 (1935). In Gregory, the Court held that a corporate reorganization that complied with the literal terms of the statute could nevertheless be disregarded for tax purposes where it was "a mere device" that "put on the form of a corporate reorganization as a disguise for concealing its real character" and was "in fact an elaborate and devious form of conveyance masquerading as a corporate reorganization." Id. at 469-70. The Gregory decision established the foundational principle that the tax treatment of a transaction must reflect its economic substance and not merely its legal form.

Following Gregory, courts developed several related but analytically distinct doctrines that collectively allow the IRS and courts to look beyond the form of a transaction to its substance:

• Economic Substance Doctrine: A transaction will be respected for tax purposes only if it has economic substance beyond the generation of tax benefits and was motivated by a genuine business purpose.

• Sham Transaction Doctrine: A transaction that has no economic substance and no business purpose other than tax avoidance may be disregarded entirely as a sham. This doctrine overlaps substantially with the economic substance doctrine and is sometimes treated as synonymous with it.

• Substance-Over-Form Doctrine: When the substance of a transaction differs from its form, the tax consequences should be determined based on the substance rather than the form. This doctrine is broader than the economic substance doctrine and does not necessarily require a finding that the transaction lacked economic substance; it addresses situations where the form of the transaction does not accurately characterize what actually occurred.

• Step Transaction Doctrine: A series of formally separate steps may be collapsed and treated as a single integrated transaction where the steps are in substance so interdependent that the legal relations created by one transaction would have been fruitless without completion of the series.

• Business Purpose Doctrine: A transaction must be motivated by a genuine business purpose beyond the generation of tax benefits. This doctrine was absorbed into the codified economic substance test as the second prong of § 7701(o).

Prior to codification, the federal circuits applied varying formulations of the economic substance test. Some circuits applied a conjunctive test, requiring both economic substance and business purpose. Other circuits applied a disjunctive test, under which the presence of either economic substance or a business purpose would suffice. Still other circuits applied a flexible, totality-of-the-circumstances analysis that blended the two prongs. This circuit split created uncertainty regarding the standard applicable in any given case. The enactment of § 7701(o) resolved this split in favor of the conjunctive test, requiring satisfaction of both prongs. For cases arising in the examination years at issue (TY 2017–2020), the codified conjunctive test under § 7701(o) governs.

In applying the economic substance doctrine — both before and after codification — courts have examined a number of factors relevant to whether an entity or arrangement possesses genuine economic substance:

(i) Whether the entity has meaningful operations beyond the reduction of federal income taxes, including employees, office space, and active management;

(ii) Whether the entity bears real economic risk — that is, whether it stands to gain or lose from the outcomes of its commercial activities, independent of the tax consequences;

(iii) Whether the arrangement generates a reasonable prospect of pre-tax profit (or, in the entity context, whether the entity generates revenues and incurs costs in a manner consistent with genuine commercial operations);

(iv) Whether the entity exercises independent decision-making authority or merely executes instructions from a parent or affiliate;

(v) Whether the entity's operations would be recognizable to an unrelated third party as a bona fide commercial enterprise; and

(vi) Whether the arrangement is one that unrelated parties operating at arm's length would reasonably enter into.

These factors are not applied mechanically; they inform a holistic assessment of whether the entity or arrangement has economic reality independent of its tax effects.

C. Interaction with IRC § 482

IRC § 482 grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses." The regulations under § 482 implement the arm's-length standard, which requires that the results of controlled transactions be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.

The economic substance doctrine can function as an overlay to § 482: even if intercompany pricing might satisfy the arm's-length standard when tested under the § 482 regulations, the IRS may argue that the entity itself lacks the substance necessary to be treated as the true owner of the relevant intangible property or as a bona fide contractual party to the intercompany arrangement. In this sense, the economic substance doctrine operates at a more fundamental level than the § 482 arm's-length pricing analysis. The § 482 analysis assumes that the entities participating in the controlled transaction are genuine participants and then tests whether the price or allocation between them reflects arm's-length terms. The economic substance doctrine challenges the premise itself — whether the entity should be recognized as a participant at all.

This distinction has important practical consequences. Under § 482, a taxpayer can defend its intercompany pricing by demonstrating that the prices charged are consistent with comparable uncontrolled transactions or with arm's-length functional and economic benchmarks. If the IRS proposes an adjustment under § 482, the taxpayer can assert a reasonable-cause defense under § 6662(e)(3)(B) based on its contemporaneous transfer pricing documentation. However, if the IRS instead challenges the entity's economic substance under § 7701(o), the analytical framework shifts: the question is no longer whether the price was right, but whether the entity deserved to be a party to the transaction in the first place. And, as discussed below in Section III.E, the penalty regime shifts as well.

Treasury Regulation § 1.482-1(d)(3)(ii)(B) provides an important bridge between the § 482 regulations and the substance inquiry. This regulation states that the arm's-length result of a controlled transaction must be determined by reference to the functions actually performed, the risks actually borne, and the assets actually employed by the controlled taxpayers. This requirement ensures that the arm's-length analysis is grounded in the economic reality of the controlled transaction and not merely in the contractual terms. If a controlled entity is contractually assigned functions, risks, and assets that it does not in fact perform, bear, or employ, then the arm's-length analysis must be adjusted to reflect the actual functional profile. This regulatory requirement parallels the DEMPE framework under the OECD Guidelines (discussed in Section IV below) and provides a statutory basis for examining the substance of the controlled entity's participation in the intercompany arrangement.

The "realistic alternative" concept embedded in the § 482 regulations is also relevant. Under this concept, the IRS may challenge an intercompany arrangement on the ground that the arrangement is one that would not be entered into by unrelated parties dealing at arm's length, because no unrelated party would agree to the terms or structure of the arrangement given the actual functional and risk profile of the parties. If the IRS contends that no unrelated party would grant PBI IP ownership and CSA participation rights given PBI's functional profile, this argument effectively merges the § 482 realistic-alternative analysis with the economic substance inquiry.

D. Key Case Law on Economic Substance in the International Tax / Transfer Pricing Context

1. Altera Corp. v. Commissioner (9th Cir. 2019)

In Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019) (en banc), cert. denied, 141 S. Ct. 131 (2020), the Ninth Circuit addressed whether Treasury Regulation § 1.482-7(d)(2), which requires that stock-based compensation costs be included in the cost pool of a qualified cost-sharing arrangement, was a valid exercise of the Treasury Department's rulemaking authority. The taxpayer, Altera Corporation, argued that the regulation was arbitrary and capricious under the Administrative Procedure Act because the Treasury had not demonstrated that unrelated parties in arm's-length transactions would share stock-based compensation costs.

The Ninth Circuit, sitting en banc, reversed the Tax Court and upheld the validity of the regulation. The court held that Treasury had a reasonable basis for concluding that stock-based compensation represents a real economic cost that should be included in the CSA cost pool. The court applied Chevron deference and found that the regulation was a permissible construction of § 482.

The relevance of Altera to PBI's situation is twofold. First, the decision affirmed the validity of the CSA regulations under Treas. Reg. § 1.482-7 and the Treasury's authority to prescribe rules ensuring that cost-sharing arrangements reflect arm's-length allocations. This affirms the regulatory framework within which PPC and PBI structured their CSA. Second, the Altera decision contains discussion — both in the majority opinion and in the briefing before the court — of the substance requirements applicable to controlled participants in a CSA. The decision reinforces the principle that a CSA participant must be a genuine entity that can and does participate in the cost-sharing arrangement in a meaningful way, rather than serving as a mere nominal co-funder. PBI's substantial operational presence, employee base, and functional activities distinguish it from the type of entity that might be challenged as a nominal participant.

2. Harborview Corporation, Inc. v. Commissioner (8th Cir. 2022; T.C. Memo. 2016-112, remanded)

Harborview Corporation, Inc. v. Commissioner is among the most significant transfer pricing decisions in recent years. The case addressed the appropriate transfer pricing method for royalties paid by Harborview Corporation's Puerto Rico manufacturing subsidiary (MPROC) to Harborview Corporation's U.S. parent for the right to manufacture and sell medical devices. The IRS proposed a comparable profits method ("CPM") analysis that would have attributed routine returns to MPROC and residual profits to the U.S. parent. Harborview Corporation argued that the comparable uncontrolled transaction ("CUT") method, based on a license agreement between Harborview Corporation and an unrelated party (Pacesetter), was the best method.

The Tax Court, in T.C. Memo. 2016-112, rejected both the IRS's and the taxpayer's proposed methods and developed its own modified CUT analysis, arriving at a royalty rate of approximately 44%. Both parties appealed to the Eighth Circuit. In Harborview Corporation, Inc. v. Commissioner, 17 F.4th 1252 (8th Cir. 2021), reh'g denied, (8th Cir. 2022), the Eighth Circuit vacated the Tax Court's decision and remanded, holding that the Tax Court had not adequately explained its analysis and had failed to apply the best method rule in a transparent manner.

The relevance of Harborview Corporation to PBI's defense lies in the extensive analysis — by both the Tax Court and the Eighth Circuit — of the functions performed, risks borne, and assets employed by the foreign subsidiary (MPROC) in determining the appropriate arm's-length pricing. The courts emphasized that a proper functional analysis is essential to determining the best transfer pricing method and that the attribution of income to a foreign subsidiary must be justified by the substance of the subsidiary's operations. The Harborview Corporation decisions illustrate that courts are willing to engage in detailed factual analysis of a foreign subsidiary's functional profile and that the entity's substantive contributions to the value chain are a critical input to the arm's-length analysis. PBI's functional profile — encompassing regulatory affairs, commercial strategy, supply-chain management, and independent pricing authority across 68 markets — is substantially more robust than the manufacturing-focused operations of MPROC, which supports PBI's position as a substantive participant entitled to residual (not merely routine) returns.

Additionally, the Harborview Corporation decisions are noteworthy for their engagement with the OECD Transfer Pricing Guidelines as a source of persuasive authority. Both the Tax Court and the Eighth Circuit referenced the OECD Guidelines in analyzing the functional profiles of the controlled entities and the appropriateness of the various transfer pricing methods. This supports our strategy of relying on the OECD DEMPE framework as a persuasive analytical tool in PBI's defense.

3. Hollowell & Co. v. Commissioner (T.C. Memo. 2017-25)

In Hollowell & Co. v. Commissioner, T.C. Memo. 2017-25, the Tax Court addressed the valuation of a platform contribution transaction ("PCT") payment made by Amazon's Luxembourg subsidiary (Axomrel Europe Holding Technologies SCS, "AEHT") to Hollowell & Co. in connection with a cost-sharing arrangement. The IRS challenged the PCT valuation, arguing that the taxpayer's valuation methodology understated the value of the pre-existing intangibles transferred to AEHT and proposed significant upward adjustments.

The Tax Court analyzed the substance of the Luxembourg subsidiary's role in considerable detail, including its decision-making authority, personnel, and commercial activities. The court examined whether AEHT possessed the capacity and authority to exploit the intangible property in its assigned territory, and whether AEHT's operational profile justified its participation in the CSA as a co-developer entitled to residual returns from the exploitation territory. The court ultimately determined the PCT value using an income-method analysis, though it disagreed with both the taxpayer's and the IRS's proposed discount rates. Notably, the IRS and the taxpayer disputed the appropriate WACC, paralleling the WACC dispute in PBI's case (where the IRS has indicated a preliminary position of 7.2% versus PPC/Whitmore Valuation Group's 9.8%).

The Amazon decision is directly relevant to PBI's defense because it confirms that the Tax Court will examine the substance of a foreign CSA participant's operations as part of the transfer pricing analysis. The court's analysis underscores the importance of demonstrating that the foreign entity has genuine decision-making authority, a meaningful workforce, and active commercial operations — all factors that PBI can demonstrate. The Amazon decision also illustrates the importance of robust documentation of the foreign entity's operational and decision-making activities, which reinforces our documentation priorities discussed in Section VI below.

4. Tarrant Group v. Commissioner (T.C. Memo. 2009-281)

In Tarrant Group v. Commissioner, T.C. Memo. 2009-281, the Tax Court addressed the valuation of a cost-sharing buy-in payment in connection with a qualified CSA between Veritas Software Corporation and its Irish subsidiary, Veritas Ireland. The IRS challenged the taxpayer's buy-in valuation and proposed a significantly higher payment. The court ultimately determined the buy-in value using a comparable uncontrolled transaction analysis.

Relevant to the present analysis, the Veritas decision examined whether the foreign CSA participant had the capacity to exploit the intellectual property in its territory and whether the functions performed by the foreign participant justified its cost-sharing allocation. The court considered the foreign participant's operational profile, including its personnel, regulatory and commercial activities, and decision-making authority. While the Veritas decision predates the codification of the economic substance doctrine in § 7701(o) and the articulation of the DEMPE framework in the revised OECD Guidelines, it is consistent with the principle that a foreign CSA participant must demonstrate meaningful functional contributions to justify its participation and income attribution.

5. Guidant LLC v. Commissioner (T.C. Memo. 2021-46)

In Guidant LLC v. Commissioner, T.C. Memo. 2021-46, the Tax Court examined the transfer pricing of a medical device manufacturer's intercompany transactions with its foreign affiliates. The court analyzed the functions performed by the foreign entities and assessed whether the foreign entities' functional profiles were consistent with their contractual roles and the income attributed to them.

The Guidant decision is relevant as a recent example of the Tax Court's willingness to scrutinize the substance of foreign entities in transfer pricing disputes and to adjust intercompany pricing where the foreign entity's functional profile does not support its contractual role. The decision reinforces the importance of demonstrating that PBI's operational activities are commensurate with its role as IP owner and CSA participant, and that the income attributed to PBI is justified by the DEMPE functions PBI actually performs.

Taken together, these decisions establish a consistent pattern in the case law: courts will examine the substance of a foreign entity's operations in the context of transfer pricing disputes, and the entity's functional profile — including its personnel, decision-making authority, risk assumption, and operational activities — is a critical determinant of whether the entity's role and income attribution will be respected. PBI's substantial operational presence, independent decision-making, and active DEMPE functions position it favorably under this body of case law.

E. Penalty Implications of the Economic Substance Doctrine

The penalty implications of the IRS's choice of legal theory are significant and must be considered in developing PPC's defense strategy.

IRC § 6662(b)(6) imposes a 20% penalty on any underpayment of tax attributable to any disallowance of claimed tax benefits by reason of a transaction lacking economic substance (as defined in § 7701(o)) or failing to meet the requirements of any similar rule of law. This penalty is a strict-liability penalty: under IRC § 6662(i), the reasonable-cause exception of § 6664(c) does not apply to any portion of an underpayment attributable to a transaction lacking economic substance. Moreover, under § 6662(i)(2), if the taxpayer did not adequately disclose the relevant facts affecting the tax treatment of the transaction in the return or in a statement attached to the return, the penalty is increased to 40%.

This strict-liability penalty regime stands in sharp contrast to the penalty framework applicable to transfer pricing adjustments under IRC § 6662(e), which imposes a 20% penalty for substantial valuation misstatements (increasing to 40% for gross valuation misstatements) but allows a reasonable-cause defense under IRC § 6662(e)(3)(B) where the taxpayer demonstrates that it acted in good faith and maintained contemporaneous documentation establishing that its transfer pricing satisfied the arm's-length standard. PPC has prepared and maintained contemporaneous transfer pricing documentation for the CSA and the legacy IP royalty arrangement, which would support a reasonable-cause defense under § 6662(e)(3)(B) if the IRS's challenge is framed exclusively as a § 482 arm's-length pricing adjustment.

The strategic significance of this distinction cannot be overstated. If the IRS reclassifies its challenge from a § 482 transfer pricing adjustment to a § 7701(o) economic substance challenge — or advances both theories simultaneously — PPC would lose the benefit of its contemporaneous documentation defense as to any underpayment attributable to the economic substance challenge. The strict-liability penalty under § 6662(b)(6) would apply regardless of whether PPC acted in good faith and maintained robust documentation. This makes it critical to defeat any economic substance challenge entirely, rather than relying on a fall-back defense of reasonable cause and contemporaneous documentation.

We should anticipate that the IRS may pursue a dual strategy: asserting both a § 482 arm's-length pricing adjustment and, in the alternative, an economic substance challenge under § 7701(o). This approach would maximize the IRS's leverage by creating penalty exposure under § 6662(b)(6) even if the § 482 pricing adjustment is modest. The involvement of IRS Chief Counsel Attorney-Advisor Franklin Rosario in the examination suggests that the IRS may already be developing legal theories beyond the standard § 482 adjustment.

Our defense strategy should therefore address both levels of the IRS's anticipated challenge: (1) demonstrate that PBI has economic substance and that § 7701(o) does not apply; and (2) demonstrate that the intercompany pricing (CSA ratios and royalty rates) satisfies the arm's-length standard under § 482. The substance analysis informs and strengthens both defenses.

IV. The DEMPE Framework Under OECD Transfer Pricing Guidelines

A. Overview of DEMPE

The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as subsequently updated in 2022) provide the internationally recognized framework for the analysis of transfer pricing in controlled transactions. Chapter VI of the OECD Guidelines addresses "Special Considerations for Intangibles" and establishes the DEMPE framework at paragraphs 6.32 through 6.71.

DEMPE is an acronym for the five categories of functions relevant to determining which entity in a multinational group should be entitled to returns from intangible property:

D — Development: Activities related to the creation and advancement of intangible property, including research and development, clinical trials, formulation, process development, and design.

E — Enhancement: Activities that improve, expand, or augment the value of existing intangible property, including line extensions, new indications or formulations, additional clinical or technical data, and improvements to manufacturing processes.

M — Maintenance: Activities that preserve and sustain the value of intangible property over time, including quality control, regulatory compliance, pharmacovigilance and adverse-event reporting, patent prosecution and renewal, and ongoing quality assurance.

P — Protection: Activities that defend intangible property rights against infringement, misappropriation, or dilution, including patent enforcement, trademark defense, trade-secret protection, anti-counterfeiting measures, and related litigation.

E — Exploitation: Activities related to the commercialization and monetization of intangible property, including marketing, sales, pricing, distribution, market access, customer relationships, and related commercial operations.

The DEMPE framework embodies a core principle of the OECD Guidelines: legal ownership of intangible property, standing alone, does not entitle an entity to the returns generated by that property. Rather, the returns from intangible property should be attributed to the entity or entities that perform, or control the performance of, important DEMPE functions, use important assets in connection with those functions, and assume and manage economically significant risks associated with those functions. An entity that holds legal title to intangible property but does not perform — or control the performance of — important DEMPE functions, does not use important assets, and does not assume and manage economically significant risks, is entitled to no more than a risk-free return (or a return appropriate to a funding-only role, adjusted for the risk of the funding activity).

This principle has significant implications for multinational pharmaceutical groups like PPC. In the pharmaceutical industry, the value of intangible property — patents, clinical data, marketing authorizations, know-how, and brand value — is the primary driver of profitability. The DEMPE framework requires that the returns from pharmaceutical IP be attributed to the entity or entities that contribute to the creation, maintenance, and exploitation of that value through their functional activities, risk assumption, and asset deployment. A foreign subsidiary that holds IP rights but serves merely as a "brass plate" entity without substantive operations would not, under the DEMPE framework, be entitled to the returns associated with that IP.

While the OECD Transfer Pricing Guidelines are not binding U.S. law, they are treated as persuasive authority by the IRS and by U.S. courts, particularly in transfer pricing disputes. As discussed in Section III.D above, both the Tax Court and the federal circuit courts have referenced the OECD Guidelines in analyzing transfer pricing issues. The IRS itself relies on OECD DEMPE concepts in its audit practice, and the examination team in this matter has referenced DEMPE in its initial IDRs. Accordingly, the DEMPE framework provides a useful analytical structure for evaluating and defending PBI's substance, even though the U.S. transfer pricing regulations do not expressly adopt the DEMPE terminology.

B. Application of Each DEMPE Function

1. Development. Definition. Under the OECD Guidelines, "Development" encompasses the research and development activities that lead to the creation of intangible property. In the pharmaceutical context, this includes basic research, drug discovery, preclinical studies, clinical trials (Phase I through Phase III), formulation development, process development, and related regulatory activities necessary to obtain marketing authorization.

PPC's Role. PPC conducts the substantial majority of R&D activities from its headquarters in Princeton Junction, New Jersey. PPC's R&D function includes approximately 2,800 scientists, researchers, and clinical development professionals. PPC's laboratories, clinical trial management operations, and core drug discovery programs are located primarily in the United States. PPC is the primary executor of the R&D activities funded through the CSA cost pool.

PBI's Role. PBI co-funds the R&D activities through its cost-sharing payments under the CSA, contributing 38.2% to 42.7% of the total annual R&D cost pool during the examination years ($186.15 million to $255.52 million annually). PBI's co-funding represents a substantial financial commitment to the Development function. In addition to funding, PBI provides input on non-Americas regulatory requirements that influence development priorities. PBI's regulatory affairs team in Dublin monitors evolving regulatory standards in the non-Americas territory (including EMA scientific guidelines, HPRA requirements, and requirements of other national regulatory agencies) and communicates those requirements to PPC's R&D team so that development programs are designed to support regulatory filings in both the Americas and non-Americas territories. PBI also employs regulatory affairs personnel who contribute to regulatory strategy for non-Americas-specific filings, including the preparation and submission of marketing authorization applications tailored to the regulatory requirements of individual country markets.

Key Question. Whether co-funding R&D activities plus regulatory input constitutes sufficient participation in the "Development" function, or whether the actual physical conduct of bench-level R&D is required.

Analysis. Under the OECD Guidelines (paragraphs 6.56–6.58), an entity can meaningfully participate in the Development function through a combination of control over and financing of development activities, coupled with bearing development risk. The Guidelines do not require that an entity physically conduct laboratory research in order to participate in the Development function; rather, the entity must exercise control over the development process, contribute to the development through its financial resources and functional inputs, and bear the economic risk of unsuccessful development outcomes. PBI satisfies these requirements: PBI commits substantial capital to the R&D cost pool through its cost-sharing payments; PBI provides functional input through its regulatory affairs team; and PBI bears the economic risk that R&D investments may not yield commercially viable products in its territory (including the risk of clinical trial failure, regulatory rejection, and market non-acceptance). Under the CSA, PBI has a contractual right to the results of the co-funded R&D for its territory and bears the financial consequences of R&D success or failure. The Ninth Circuit's decision in Altera affirms the validity of cost-sharing arrangements that allocate development costs and rights on this basis. PBI's participation in the Development function is therefore assessed as moderate-to-strong.

2. Enhancement. Definition. "Enhancement" encompasses activities that improve, expand, or augment the value of existing intangible property. In the pharmaceutical context, this includes line extensions (new dosage forms, new routes of administration), new indication studies, reformulations, post-marketing clinical studies, and the generation of additional clinical data that supports expanded use or market access.

PPC's Role. PPC's U.S.-based R&D team leads the majority of enhancement activities, including the design and execution of new indication studies and the development of new formulations.

PBI's Role. PBI makes meaningful contributions to the Enhancement function in several ways. PBI initiates and funds non-Americas-specific clinical studies, including studies required by non-Americas regulatory agencies as conditions of marketing authorization or post-marketing commitments. PBI contributes to post-marketing studies that generate real-world evidence supporting the continued use and expanded access of PPC's products in non-Americas markets. PBI's regulatory affairs and medical affairs teams provide market intelligence that informs enhancement decisions, including feedback from non-Americas healthcare professionals, payers, and regulatory agencies regarding unmet clinical needs, competitive dynamics, and regulatory expectations. PBI's cumulative regulatory expenditure of €47.2 million over the 2017–2020 period reflects the costs associated with regulatory submissions, marketing authorization applications, and post-marketing commitments, many of which involve activities that enhance the value of the underlying intangible property by expanding its geographic footprint, securing new indications, or generating additional clinical evidence. PBI's participation in the Enhancement function is assessed as moderate.

3. Maintenance. Definition. "Maintenance" encompasses activities that preserve the value of intangible property over time. In the pharmaceutical context, this includes regulatory compliance (maintaining marketing authorizations, filing variations and renewals, responding to regulatory inquiries), pharmacovigilance (adverse event monitoring and reporting), quality control, and patent prosecution and renewal.

PPC's Role. PPC manages the global patent portfolio and conducts U.S.-focused pharmacovigilance and quality-control activities.

PBI's Role. PBI performs extensive Maintenance functions for the non-Americas territory. PBI manages regulatory compliance across 68 country markets, which involves the ongoing maintenance of marketing authorizations (including periodic renewal applications, Type IA, Type IB, and Type II variations, and responses to regulatory agency queries), compliance with labeling requirements, and monitoring of evolving regulatory standards. PBI manages relationships with non-Americas regulatory agencies, including direct engagement with the EMA, the HPRA, the MHRA, and national regulatory agencies throughout Europe, Asia-Pacific, the Middle East, and Africa. PBI maintains local pharmacovigilance operations, including adverse event monitoring, signal detection, periodic safety update report preparation, and risk management plan implementation for the non-Americas territory. PBI employs dedicated medical-affairs staff in Dublin who manage medical information inquiries, medical education programs, and advisory board relationships with non-Americas key opinion leaders.

The evidence supporting PBI's Maintenance function includes: PBI's regulatory submission expenditures (€47.2 million cumulative, a portion of which relates to maintenance activities); PBI's medical-affairs headcount; PBI's pharmacovigilance infrastructure; and the documented compliance activities across 68 country markets. PBI's participation in the Maintenance function is assessed as strong.

4. Protection. Definition. "Protection" encompasses activities that defend intangible property rights against infringement, misappropriation, or dilution. In the pharmaceutical context, this includes patent enforcement and defense, trademark registration and defense, trade-secret protection, anti-counterfeiting measures, and related litigation and enforcement activities.

PPC's Role. PPC manages global patent prosecution (preparation and filing of patent applications) and leads primary patent litigation management, including Hatch-Waxman proceedings in the United States and major cross-border patent disputes.

PBI's Role. PBI manages local IP enforcement in non-Americas territories, including the coordination of patent enforcement actions in European and other jurisdictions, coordination with local external counsel on trademark and patent matters, and engagement in anti-counterfeiting measures in non-Americas markets. PBI's in-house legal team, supported by external local counsel, monitors for potential IP infringements in PBI's territory and takes enforcement action where necessary. PBI also manages trademark registrations and renewals in non-Americas jurisdictions, ensuring that the PPC product trademarks are protected across PBI's distribution markets.

While PPC maintains primary responsibility for global patent prosecution and major litigation, PBI's contributions to the Protection function in its territory are meaningful. PBI exercises authority over local enforcement decisions, selects and manages local counsel, and bears the costs of local IP enforcement. PBI's participation in the Protection function is assessed as moderate.

5. Exploitation. Definition. "Exploitation" encompasses the commercialization and monetization of intangible property — the activities through which IP is converted into revenue. In the pharmaceutical context, this includes marketing, sales, pricing, market access, distribution, customer (healthcare provider and payer) relationships, and supply-chain management.

PBI's Role. Exploitation is PBI's strongest DEMPE function. PBI serves as the commercial principal for the non-Americas territory and performs the full range of Exploitation functions:

• Independent Pricing Authority: PBI makes independent pricing decisions across 68 non-Americas country markets. Pricing decisions are made by PBI's commercial strategy team in Dublin, informed by market-specific analyses of competitive dynamics, payer requirements, reimbursement frameworks, and regulatory constraints. PBI's pricing committee meets regularly and documents its pricing decisions and the rationale therefor.

• Distribution Partner Management: PBI selects and manages distribution partners in markets where PBI does not maintain a direct sales presence. PBI negotiates distribution agreements, monitors distributor performance, and makes decisions regarding distributor appointment, retention, and termination.

• Market Entry Strategy: PBI determines market entry strategy and timing for new products and new geographic markets within its territory. PBI evaluates market opportunity, regulatory pathway, competitive landscape, and commercial feasibility for each potential market en

RESEARCH MEMORANDUM PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
TO: Leonard Cross, Responsible Partner Garrett Simmons, Lead Associate
FROM: Leila Nazari, Working Associate
DATE: August 18, 2022
RE: Economic Substance Doctrine and DEMPE Functions Analysis — Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination Defense (TY 2017–2020)
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp.
This memorandum is protected by the attorney-client privilege and constitutes attorney work product prepared in anticipation of litigation. It is intended solely for the use of the individuals to whom it is addressed and should not be disclosed, distributed, or copied without the express prior authorization of the responsible partner. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the economic substance doctrine as applied in the transfer pricing context and the DEMPE framework — encompassing the functions of Development, Enhancement, Maintenance, Protection, and Exploitation — under the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as revised in 2022), with specific application to the IRS's anticipated challenge to Penterra Biopharma International DAC ("PBI") as a qualified participant in the cost-sharing arrangement ("CSA") with Penterra Pharmaceuticals Corp. ("PPC").
The IRS Large Business & International Division ("LB&I") has opened an examination of PPC's tax years 2017 through 2020, assigned Exam Team ID LB&I-NE-TP-2022-00641 and initiated on May 16, 2022. Based on preliminary Information Document Requests ("IDRs") and the scope of the examination as communicated during the opening conference, the IRS has indicated that it may challenge PBI's economic substance as an intellectual property owner and CSA participant, asserting that key DEMPE functions remained in the United States — principally at PPC's headquarters in Princeton Junction, New Jersey. If the IRS sustains this challenge, it could serve as the basis for proposed adjustments to PBI's cost-sharing ratios and royalty rates, potentially reallocating significant income from PBI to PPC for U.S. federal income tax purposes. Additionally, if the IRS frames its challenge under the economic substance doctrine codified at IRC § 7701(o), rather than — or in addition to — a straightforward § 482 arm's-length pricing adjustment, PPC could face strict-liability penalties under IRC § 6662(b)(6) without the benefit of a reasonable-cause defense predicated on contemporaneous transfer pricing documentation.
Conclusion. Based on the analysis set forth below, it is my assessment that PBI possesses sufficient economic substance to justify its role as IP owner and CSA participant for the non-Americas territory. This conclusion is supported by PBI's substantial and growing headcount (185 employees by 2020), its independent decision-making authority exercised by a Dublin-based management team led by Managing Director Aidan Naughton, its significant capital commitments under the CSA (including aggregate annual cost-sharing payments ranging from $186.15 million to $255.52 million during the exam period and a platform contribution transaction payment of $312 million), and its performance of meaningful DEMPE functions in Ireland. PBI is not a passive "cash box" or shell entity. It operates an active commercial enterprise responsible for the regulatory, commercial, and supply-chain management of PPC's pharmaceutical products across 68 non-Americas country markets. The economic substance doctrine, properly applied under § 7701(o) and the supporting body of case law, does not support recharacterization of PBI's role.
This memorandum proceeds as follows: Section II sets forth the relevant background facts. Section III provides the legal framework governing the economic substance doctrine, including its codification, common law origins, interaction with IRC § 482, key case law, and penalty implications. Section IV analyzes the DEMPE framework under the OECD Transfer Pricing Guidelines. Section V applies the legal framework to PBI's specific facts. Section VI offers strategic recommendations for PPC's defense. Section VII provides overall conclusions. Supporting appendices summarize PBI's DEMPE functions, the relevant statutory and regulatory authorities, and key case law.
II. Background Facts Relevant to the Analysis
The following factual summary is based on a review of corporate organizational documents, intercompany agreements, PBI board minutes, PPC and PBI financial statements, the CSA and amendments thereto, PBI human-resources records, regulatory filing documentation, and discussions with PPC's in-house tax department (Vice President of Tax, Margaret Reyes). This summary will be supplemented as additional documentation is gathered through the IDR process and in coordination with PBI's Irish counsel, Thornbury & Keogh.
A. Corporate Structure
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC's headquarters are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is the ultimate parent of a multinational group that discovers, develops, manufactures, and commercializes pharmaceutical products globally. As of 2020, PPC employed approximately 14,500 employees worldwide and reported consolidated global revenues in excess of $7.8 billion.
PPC's international structure relevant to this analysis is as follows:
PPC owns 100% of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg. PHL's registered office is located at 14, rue Aldringen, L-1118 Luxembourg. For U.S. federal income tax purposes, PHL has elected to be treated as a disregarded entity under Treas. Reg. § 301.7701-3 (check-the-box election effective as of PHL's date of formation). Accordingly, for U.S. tax purposes, PPC is treated as the direct owner of PHL's subsidiary.
PHL owns 100% of Penterra Biopharma International DAC ("PBI"), a Designated Activity Company organized under the laws of Ireland. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI's Irish tax reference number is 3218764T. PBI serves as the principal entity for the commercialization and exploitation of PPC's pharmaceutical intellectual property in all territories outside the Americas (i.e., excluding North America, Central America, South America, and the Caribbean).
Additionally, Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company with its registered office and manufacturing facility located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland (Companies Registration Office Number 512347). PMI operates as a contract manufacturer for PBI, producing pharmaceutical products for the non-Americas markets under a contract manufacturing agreement at a cost-plus markup of 8%. PMI employs approximately 620 employees at its Cork facility and operates under good manufacturing practice ("GMP") standards as required by the European Medicines Agency ("EMA"), the Irish Health Products Regulatory Authority ("HPRA"), and the applicable regulatory authorities in PBI's distribution markets. PMI's contract manufacturing arrangement with PBI is a separate intercompany agreement that is also within the scope of the IRS examination, though the primary focus of this memorandum is on PBI's role as IP owner and CSA participant.
B. The Cost-Sharing Arrangement and IP Structure
PBI was incorporated on March 15, 2012. The CSA between PPC and PBI was executed and became effective on July 1, 2012. The CSA was structured as a qualified cost-sharing arrangement ("QCSA") within the meaning of Treas. Reg. § 1.482-7. Under the CSA, PBI acquired the right to develop and exploit PPC's existing and future pharmaceutical intellectual property outside the Americas in exchange for two categories of consideration:
First, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC. The PCT payment compensated PPC for making its existing pre-CSA intellectual property — including approved and pipeline pharmaceutical compounds, related know-how, clinical trial data, and regulatory filings — available to PBI for development and exploitation in the non-Americas territory. The PCT payment was determined using a discounted cash flow methodology based on projected income streams from the non-Americas territory. We note that the IRS and PPC's economic advisors have differed on the appropriate weighted average cost of capital ("WACC") applied in the PCT valuation: the IRS has indicated a preliminary position that a 7.2% WACC is appropriate, while Whitmore Valuation Group LLC (PPC's retained economic expert) has applied a 9.8% WACC. This valuation dispute is addressed separately in Dr. Helena Vasquez's expert analysis and is not the primary focus of this memorandum, though the PCT valuation methodology and any associated adjustments may interact with the substance analysis discussed herein.
Second, under the CSA, PBI makes ongoing annual cost-sharing payments to PPC in proportion to PBI's reasonably anticipated benefits ("RAB") from the intangible development activities funded through the arrangement. The cost-sharing percentages and absolute payment amounts for the examination years are as follows:
The gradual increase in PBI's cost-sharing percentage over the examination period reflects the growing proportional share of reasonably anticipated benefits attributable to PBI's non-Americas territory, driven by expanding market penetration, regulatory approvals in additional jurisdictions, and favorable revenue trends in PBI's markets relative to the Americas.
In addition to the CSA, PBI maintains a legacy IP royalty arrangement under which PBI licenses certain pre-2012 compounds from PPC at a royalty rate of 4.5% of net sales for the non-Americas territory. This royalty covers compounds that were fully developed and commercialized prior to the CSA effective date and were not included in the PCT calculation.
PPC's product portfolio includes three key products with significant global and non-Americas revenue:
• Veritaxol (oncology): Global net sales of $3.12 billion (2020), of which $1.34 billion was attributable to non-Americas markets (PBI territory).
• Imvara (immunology): Global net sales of $1.87 billion (2020), of which $0.79 billion was attributable to non-Americas markets.
• Cerulon (rare disease): Global net sales of $0.62 billion (2020), of which $0.28 billion was attributable to non-Americas markets.
These three products collectively accounted for approximately $2.41 billion in non-Americas net sales in 2020, representing the majority of PBI's revenue base. PBI also commercializes additional products in the PPC portfolio across its territory, contributing to PBI's total FY 2020 revenue of €2.14 billion.
C. PBI's Operations and Substance in Ireland
PBI has maintained and expanded a meaningful operational presence in Ireland since its incorporation in 2012. The following facts are drawn from PBI's human-resources records, organizational charts, financial statements, real-property leases, board meeting records, and regulatory filing documentation.
Headcount and Personnel. PBI's headcount has grown organically from 52 employees at the time of its establishment in 2012 to 185 employees by the end of fiscal year 2020. PBI's Managing Director is Aidan Naughton, who is based in Dublin and reports to PBI's board of directors. Mr. Naughton has served as Managing Director since 2013 and exercises day-to-day authority over PBI's commercial, regulatory, and operational functions. PBI's Dublin-based workforce includes personnel in the following functional areas: regulatory affairs, medical affairs, commercial strategy, supply-chain management, finance, legal, human resources, and information technology. PBI's employees are not mere nominal appointees; they occupy substantive roles with genuine decision-making responsibility over PBI's commercial operations in the non-Americas territory.
Functional Activities. PBI's core functions include: (a) regulatory affairs — preparation, submission, and management of marketing authorization applications and variations across 68 non-Americas country markets, including submissions to the EMA, the HPRA, the UK Medicines and Healthcare products Regulatory Agency ("MHRA"), and numerous national regulatory agencies; (b) medical affairs — management of post-marketing surveillance, adverse event reporting, and medical information inquiries for the non-Americas territory; (c) commercial strategy — development and execution of pricing strategies, reimbursement negotiations with government payers and private insurers, market-access initiatives, and launch planning for new products and new market entries; and (d) supply-chain management — coordination of manufacturing with PMI in Cork, management of logistics and distribution to non-Americas markets, inventory planning, and quality assurance oversight of the non-Americas supply chain.
Commercial Decision-Making. PBI bears market risk for the non-Americas territory and makes key commercial decisions independently of PPC. Specifically, PBI exercises independent authority over pricing across 68 country markets, market entry decisions (including the sequencing and prioritization of new country launches), and the selection and management of distribution partners in markets where PBI does not maintain a direct sales presence. PBI's pricing decisions are documented in internal pricing committee meeting records, which reflect market-specific analysis of competitive dynamics, regulatory requirements, payer negotiations, and profitability targets. PPC does not dictate PBI's pricing or market-entry decisions, though PPC exercises normal oversight as the ultimate parent in a multinational group.
Office Space. PBI occupies approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, under a long-term lease. The office houses PBI's management team, regulatory affairs department, commercial strategy group, supply-chain coordination function, and administrative support staff.
Board Governance. PBI's board of directors convenes quarterly meetings in Dublin. Over the examination period (TY 2017–2020), PBI held a total of 42 board meetings, including regularly scheduled quarterly meetings and special sessions convened to address significant commercial and regulatory matters. All 42 meetings were held in Dublin. The board meetings are documented through formal agendas and minutes, which reflect substantive discussion and deliberation on matters including: annual budgets and financial performance, cost-sharing calculations, regulatory strategy, commercial performance by product and by market, capital expenditure approvals, supply-chain matters, and risk management. The board minutes will be a critical category of evidence in demonstrating PBI's independent decision-making authority and governance integrity.
Regulatory Expenditures. During the examination period (2017–2020), PBI incurred cumulative regulatory expenditures of €47.2 million related to regulatory submissions, marketing authorization applications, post-marketing commitments, and regulatory compliance across 68 non-Americas country markets. These expenditures represent capital investments in the regulatory infrastructure necessary to commercialize PPC's products outside the Americas and constitute a meaningful contribution to the Development, Enhancement, and Maintenance of the underlying pharmaceutical IP.
Banking and Financial Independence. PBI maintains an independent banking relationship with Glenmore Bank Ireland plc. PBI operates its own treasury function and manages its own cash flows, including collections from non-Americas customers, payments to PMI under the contract manufacturing arrangement, cost-sharing payments to PPC under the CSA, and royalty payments to PPC under the legacy IP license.
Financial Profile. PBI's fiscal year 2020 financial results reflect a substantial commercial enterprise: total revenue of €2.14 billion and pre-tax income of €1.06 billion. PBI's Irish effective tax rate on trading income is 12.5%. Beginning in fiscal year 2016, PBI claimed relief under Ireland's Knowledge Development box ("KDB"), which provides a reduced effective tax rate of 6.25% on qualifying income derived from qualifying assets (as defined by Irish Finance Act 2015, section 769R), which in PBI's case includes income attributable to IP developed through PBI's co-funded R&D activities under the CSA. The availability and application of the KDB relief is a matter of Irish tax law and does not directly affect the U.S. federal income tax analysis, though the IRS may reference PBI's effective tax rate in framing its broader challenge to the arrangement.
D. IRS Position (Anticipated)
Based on the opening conference, the scope and content of IDRs issued to date, and informal communications between PPC's in-house tax department and the examination team, the IRS has signaled that it may advance the following position:
The IRS asserts, in part, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. Specifically, the IRS argues that the key DEMPE functions associated with PPC's pharmaceutical IP — principally the conduct of research and development activities and certain strategic management functions — remained in the United States at PPC's headquarters in Princeton Junction, New Jersey. Under this theory, PBI is characterized as primarily a funding entity that co-funded R&D costs through the CSA but did not perform the substantive functions necessary to justify its attribution of IP ownership and the associated income streams.
If sustained, this recharacterization could support the IRS's proposed adjustments in several ways: (a) recharacterization of PBI's CSA cost-sharing payments as something other than arm's-length consideration for a co-development interest, potentially leading to a reallocation of the cost-sharing ratios; (b) adjustment of the royalty rate under the legacy IP license; and (c) in the most aggressive formulation, disregard of PBI's participation in the CSA entirely, treating PPC as the sole owner and developer of the IP and PBI as a mere licensee entitled to routine returns.
The examination team assigned to this matter includes Supervisory Revenue Agent Gerald Meskill, Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and IRS Chief Counsel Attorney-Advisor Franklin Rosario. The involvement of a Chief Counsel attorney from the outset suggests that the IRS views this examination as a significant matter and may be developing legal theories beyond standard § 482 pricing adjustments.
III. Legal Framework: The Economic Substance Doctrine
A. Codification Under IRC § 7701(o)
The economic substance doctrine was codified by the Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, § 1409, 124 Stat. 1029, 1067-70 (2010), which added section 7701(o) to the Internal Revenue Code. Section 7701(o) provides that, in the case of any transaction to which the economic substance doctrine is relevant, such transaction shall be treated as having economic substance only if two conditions are met:
First, the transaction changes in a meaningful way (apart from federal income tax effects) the taxpayer's economic position. This is commonly referred to as the "economic substance" prong or the "objective" prong. The inquiry examines whether the transaction has real economic consequences beyond the generation of tax benefits. In evaluating this prong, courts and the IRS consider whether the transaction generates a meaningful pre-tax profit, involves the commitment of genuine capital at risk, and alters the taxpayer's economic position in a way that would matter absent any tax considerations.
Second, the taxpayer has a substantial purpose (apart from federal income tax effects) for entering into such transaction. This is commonly referred to as the "business purpose" prong or the "subjective" prong. This inquiry examines whether the taxpayer's motivations for entering into the transaction include a genuine non-tax business reason. The existence of a tax benefit does not negate a finding of business purpose so long as the taxpayer also had a substantial non-tax purpose for the transaction.
Critically, § 7701(o) imposes a conjunctive test: both prongs must be satisfied. A transaction that changes the taxpayer's economic position in a meaningful way but lacks a substantial non-tax business purpose will fail the test, as will a transaction that has a substantial non-tax purpose but does not change the taxpayer's economic position in a meaningful way.
Section 7701(o)(5)(C) provides that the determination of whether the economic substance doctrine is "relevant" to a transaction is made in the same manner as if § 7701(o) had never been enacted. This provision preserves the pre-codification analytical framework for determining when the doctrine applies in the first instance, while standardizing the two-prong test that applies once the doctrine is found to be relevant.
Although § 7701(o) is drafted in terms of "transactions," the economic substance analysis has been applied by the IRS and courts to entities and ongoing arrangements, not merely discrete, isolated transactions. In the transfer pricing context, the IRS may invoke the economic substance doctrine to challenge the participation of a foreign entity in intercompany transactions — such as a CSA or IP licensing arrangement — where the IRS contends that the entity lacks the operational substance to be treated as a bona fide participant. Where the entity is viewed as a shell without meaningful economic activity, the IRS may argue that the intercompany arrangement should be disregarded or recharacterized, with the associated income reallocated to the entity that possesses the substance underlying the income-generating functions.
The relevance of the economic substance doctrine to transfer pricing disputes lies in its potential to override the arm's-length analysis. Even where intercompany pricing might satisfy arm's-length standards when tested under the § 482 regulations, the IRS may argue that the entity to which income is attributed under the intercompany pricing structure lacks the economic substance necessary to be treated as the true owner, developer, or exploiter of the relevant intangible property. In effect, the economic substance doctrine functions as a threshold inquiry: before testing whether intercompany pricing is arm's-length, the IRS may first ask whether the participating entities have sufficient substance to be recognized as the parties to the transactions being tested.
B. Common Law Origins and Evolution
The economic substance doctrine has deep roots in the common law of federal taxation, tracing its origins to the Supreme Court's seminal decision in Gregory v. Helvering, 293 U.S. 465 (1935). In Gregory, the Court held that a corporate reorganization that complied with the literal terms of the statute could nevertheless be disregarded for tax purposes where it was "a mere device" that "put on the form of a corporate reorganization as a disguise for concealing its real character" and was "in fact an elaborate and devious form of conveyance masquerading as a corporate reorganization." Id. at 469-70. The Gregory decision established the foundational principle that the tax treatment of a transaction must reflect its economic substance and not merely its legal form.
Following Gregory, courts developed several related but analytically distinct doctrines that collectively allow the IRS and courts to look beyond the form of a transaction to its substance:
• Economic Substance Doctrine: A transaction will be respected for tax purposes only if it has economic substance beyond the generation of tax benefits and was motivated by a genuine business purpose.
• Sham Transaction Doctrine: A transaction that has no economic substance and no business purpose other than tax avoidance may be disregarded entirely as a sham. This doctrine overlaps substantially with the economic substance doctrine and is sometimes treated as synonymous with it.
• Substance-Over-Form Doctrine: When the substance of a transaction differs from its form, the tax consequences should be determined based on the substance rather than the form. This doctrine is broader than the economic substance doctrine and does not necessarily require a finding that the transaction lacked economic substance; it addresses situations where the form of the transaction does not accurately characterize what actually occurred.
• Step Transaction Doctrine: A series of formally separate steps may be collapsed and treated as a single integrated transaction where the steps are in substance so interdependent that the legal relations created by one transaction would have been fruitless without completion of the series.
• Business Purpose Doctrine: A transaction must be motivated by a genuine business purpose beyond the generation of tax benefits. This doctrine was absorbed into the codified economic substance test as the second prong of § 7701(o).
Prior to codification, the federal circuits applied varying formulations of the economic substance test. Some circuits applied a conjunctive test, requiring both economic substance and business purpose. Other circuits applied a disjunctive test, under which the presence of either economic substance or a business purpose would suffice. Still other circuits applied a flexible, totality-of-the-circumstances analysis that blended the two prongs. This circuit split created uncertainty regarding the standard applicable in any given case. The enactment of § 7701(o) resolved this split in favor of the conjunctive test, requiring satisfaction of both prongs. For cases arising in the examination years at issue (TY 2017–2020), the codified conjunctive test under § 7701(o) governs.
In applying the economic substance doctrine — both before and after codification — courts have examined a number of factors relevant to whether an entity or arrangement possesses genuine economic substance:
(i) Whether the entity has meaningful operations beyond the reduction of federal income taxes, including employees, office space, and active management;
(ii) Whether the entity bears real economic risk — that is, whether it stands to gain or lose from the outcomes of its commercial activities, independent of the tax consequences;
(iii) Whether the arrangement generates a reasonable prospect of pre-tax profit (or, in the entity context, whether the entity generates revenues and incurs costs in a manner consistent with genuine commercial operations);
(iv) Whether the entity exercises independent decision-making authority or merely executes instructions from a parent or affiliate;
(v) Whether the entity's operations would be recognizable to an unrelated third party as a bona fide commercial enterprise; and
(vi) Whether the arrangement is one that unrelated parties operating at arm's length would reasonably enter into.
These factors are not applied mechanically; they inform a holistic assessment of whether the entity or arrangement has economic reality independent of its tax effects.
C. Interaction with IRC § 482
IRC § 482 grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses." The regulations under § 482 implement the arm's-length standard, which requires that the results of controlled transactions be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
The economic substance doctrine can function as an overlay to § 482: even if intercompany pricing might satisfy the arm's-length standard when tested under the § 482 regulations, the IRS may argue that the entity itself lacks the substance necessary to be treated as the true owner of the relevant intangible property or as a bona fide contractual party to the intercompany arrangement. In this sense, the economic substance doctrine operates at a more fundamental level than the § 482 arm's-length pricing analysis. The § 482 analysis assumes that the entities participating in the controlled transaction are genuine participants and then tests whether the price or allocation between them reflects arm's-length terms. The economic substance doctrine challenges the premise itself — whether the entity should be recognized as a participant at all.
This distinction has important practical consequences. Under § 482, a taxpayer can defend its intercompany pricing by demonstrating that the prices charged are consistent with comparable uncontrolled transactions or with arm's-length functional and economic benchmarks. If the IRS proposes an adjustment under § 482, the taxpayer can assert a reasonable-cause defense under § 6662(e)(3)(B) based on its contemporaneous transfer pricing documentation. However, if the IRS instead challenges the entity's economic substance under § 7701(o), the analytical framework shifts: the question is no longer whether the price was right, but whether the entity deserved to be a party to the transaction in the first place. And, as discussed below in Section III.E, the penalty regime shifts as well.
Treasury Regulation § 1.482-1(d)(3)(ii)(B) provides an important bridge between the § 482 regulations and the substance inquiry. This regulation states that the arm's-length result of a controlled transaction must be determined by reference to the functions actually performed, the risks actually borne, and the assets actually employed by the controlled taxpayers. This requirement ensures that the arm's-length analysis is grounded in the economic reality of the controlled transaction and not merely in the contractual terms. If a controlled entity is contractually assigned functions, risks, and assets that it does not in fact perform, bear, or employ, then the arm's-length analysis must be adjusted to reflect the actual functional profile. This regulatory requirement parallels the DEMPE framework under the OECD Guidelines (discussed in Section IV below) and provides a statutory basis for examining the substance of the controlled entity's participation in the intercompany arrangement.
The "realistic alternative" concept embedded in the § 482 regulations is also relevant. Under this concept, the IRS may challenge an intercompany arrangement on the ground that the arrangement is one that would not be entered into by unrelated parties dealing at arm's length, because no unrelated party would agree to the terms or structure of the arrangement given the actual functional and risk profile of the parties. If the IRS contends that no unrelated party would grant PBI IP ownership and CSA participation rights given PBI's functional profile, this argument effectively merges the § 482 realistic-alternative analysis with the economic substance inquiry.
D. Key Case Law on Economic Substance in the International Tax / Transfer Pricing Context
1. Altera Corp. v. Commissioner (9th Cir. 2019)
In Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019) (en banc), cert. denied, 141 S. Ct. 131 (2020), the Ninth Circuit addressed whether Treasury Regulation § 1.482-7(d)(2), which requires that stock-based compensation costs be included in the cost pool of a qualified cost-sharing arrangement, was a valid exercise of the Treasury Department's rulemaking authority. The taxpayer, Altera Corporation, argued that the regulation was arbitrary and capricious under the Administrative Procedure Act because the Treasury had not demonstrated that unrelated parties in arm's-length transactions would share stock-based compensation costs.
The Ninth Circuit, sitting en banc, reversed the Tax Court and upheld the validity of the regulation. The court held that Treasury had a reasonable basis for concluding that stock-based compensation represents a real economic cost that should be included in the CSA cost pool. The court applied Chevron deference and found that the regulation was a permissible construction of § 482.
The relevance of Altera to PBI's situation is twofold. First, the decision affirmed the validity of the CSA regulations under Treas. Reg. § 1.482-7 and the Treasury's authority to prescribe rules ensuring that cost-sharing arrangements reflect arm's-length allocations. This affirms the regulatory framework within which PPC and PBI structured their CSA. Second, the Altera decision contains discussion — both in the majority opinion and in the briefing before the court — of the substance requirements applicable to controlled participants in a CSA. The decision reinforces the principle that a CSA participant must be a genuine entity that can and does participate in the cost-sharing arrangement in a meaningful way, rather than serving as a mere nominal co-funder. PBI's substantial operational presence, employee base, and functional activities distinguish it from the type of entity that might be challenged as a nominal participant.
2. Harborview Corporation, Inc. v. Commissioner (8th Cir. 2022; T.C. Memo. 2016-112, remanded)
Harborview Corporation, Inc. v. Commissioner is among the most significant transfer pricing decisions in recent years. The case addressed the appropriate transfer pricing method for royalties paid by Harborview Corporation's Puerto Rico manufacturing subsidiary (MPROC) to Harborview Corporation's U.S. parent for the right to manufacture and sell medical devices. The IRS proposed a comparable profits method ("CPM") analysis that would have attributed routine returns to MPROC and residual profits to the U.S. parent. Harborview Corporation argued that the comparable uncontrolled transaction ("CUT") method, based on a license agreement between Harborview Corporation and an unrelated party (Pacesetter), was the best method.
The Tax Court, in T.C. Memo. 2016-112, rejected both the IRS's and the taxpayer's proposed methods and developed its own modified CUT analysis, arriving at a royalty rate of approximately 44%. Both parties appealed to the Eighth Circuit. In Harborview Corporation, Inc. v. Commissioner, 17 F.4th 1252 (8th Cir. 2021), reh'g denied, (8th Cir. 2022), the Eighth Circuit vacated the Tax Court's decision and remanded, holding that the Tax Court had not adequately explained its analysis and had failed to apply the best method rule in a transparent manner.
The relevance of Harborview Corporation to PBI's defense lies in the extensive analysis — by both the Tax Court and the Eighth Circuit — of the functions performed, risks borne, and assets employed by the foreign subsidiary (MPROC) in determining the appropriate arm's-length pricing. The courts emphasized that a proper functional analysis is essential to determining the best transfer pricing method and that the attribution of income to a foreign subsidiary must be justified by the substance of the subsidiary's operations. The Harborview Corporation decisions illustrate that courts are willing to engage in detailed factual analysis of a foreign subsidiary's functional profile and that the entity's substantive contributions to the value chain are a critical input to the arm's-length analysis. PBI's functional profile — encompassing regulatory affairs, commercial strategy, supply-chain management, and independent pricing authority across 68 markets — is substantially more robust than the manufacturing-focused operations of MPROC, which supports PBI's position as a substantive participant entitled to residual (not merely routine) returns.
Additionally, the Harborview Corporation decisions are noteworthy for their engagement with the OECD Transfer Pricing Guidelines as a source of persuasive authority. Both the Tax Court and the Eighth Circuit referenced the OECD Guidelines in analyzing the functional profiles of the controlled entities and the appropriateness of the various transfer pricing methods. This supports our strategy of relying on the OECD DEMPE framework as a persuasive analytical tool in PBI's defense.
3. Hollowell & Co. v. Commissioner (T.C. Memo. 2017-25)
In Hollowell & Co. v. Commissioner, T.C. Memo. 2017-25, the Tax Court addressed the valuation of a platform contribution transaction ("PCT") payment made by Amazon's Luxembourg subsidiary (Axomrel Europe Holding Technologies SCS, "AEHT") to Hollowell & Co. in connection with a cost-sharing arrangement. The IRS challenged the PCT valuation, arguing that the taxpayer's valuation methodology understated the value of the pre-existing intangibles transferred to AEHT and proposed significant upward adjustments.
The Tax Court analyzed the substance of the Luxembourg subsidiary's role in considerable detail, including its decision-making authority, personnel, and commercial activities. The court examined whether AEHT possessed the capacity and authority to exploit the intangible property in its assigned territory, and whether AEHT's operational profile justified its participation in the CSA as a co-developer entitled to residual returns from the exploitation territory. The court ultimately determined the PCT value using an income-method analysis, though it disagreed with both the taxpayer's and the IRS's proposed discount rates. Notably, the IRS and the taxpayer disputed the appropriate WACC, paralleling the WACC dispute in PBI's case (where the IRS has indicated a preliminary position of 7.2% versus PPC/Whitmore Valuation Group's 9.8%).
The Amazon decision is directly relevant to PBI's defense because it confirms that the Tax Court will examine the substance of a foreign CSA participant's operations as part of the transfer pricing analysis. The court's analysis underscores the importance of demonstrating that the foreign entity has genuine decision-making authority, a meaningful workforce, and active commercial operations — all factors that PBI can demonstrate. The Amazon decision also illustrates the importance of robust documentation of the foreign entity's operational and decision-making activities, which reinforces our documentation priorities discussed in Section VI below.
4. Tarrant Group v. Commissioner (T.C. Memo. 2009-281)
In Tarrant Group v. Commissioner, T.C. Memo. 2009-281, the Tax Court addressed the valuation of a cost-sharing buy-in payment in connection with a qualified CSA between Veritas Software Corporation and its Irish subsidiary, Veritas Ireland. The IRS challenged the taxpayer's buy-in valuation and proposed a significantly higher payment. The court ultimately determined the buy-in value using a comparable uncontrolled transaction analysis.
Relevant to the present analysis, the Veritas decision examined whether the foreign CSA participant had the capacity to exploit the intellectual property in its territory and whether the functions performed by the foreign participant justified its cost-sharing allocation. The court considered the foreign participant's operational profile, including its personnel, regulatory and commercial activities, and decision-making authority. While the Veritas decision predates the codification of the economic substance doctrine in § 7701(o) and the articulation of the DEMPE framework in the revised OECD Guidelines, it is consistent with the principle that a foreign CSA participant must demonstrate meaningful functional contributions to justify its participation and income attribution.
5. Guidant LLC v. Commissioner (T.C. Memo. 2021-46)
In Guidant LLC v. Commissioner, T.C. Memo. 2021-46, the Tax Court examined the transfer pricing of a medical device manufacturer's intercompany transactions with its foreign affiliates. The court analyzed the functions performed by the foreign entities and assessed whether the foreign entities' functional profiles were consistent with their contractual roles and the income attributed to them.
The Guidant decision is relevant as a recent example of the Tax Court's willingness to scrutinize the substance of foreign entities in transfer pricing disputes and to adjust intercompany pricing where the foreign entity's functional profile does not support its contractual role. The decision reinforces the importance of demonstrating that PBI's operational activities are commensurate with its role as IP owner and CSA participant, and that the income attributed to PBI is justified by the DEMPE functions PBI actually performs.
Taken together, these decisions establish a consistent pattern in the case law: courts will examine the substance of a foreign entity's operations in the context of transfer pricing disputes, and the entity's functional profile — including its personnel, decision-making authority, risk assumption, and operational activities — is a critical determinant of whether the entity's role and income attribution will be respected. PBI's substantial operational presence, independent decision-making, and active DEMPE functions position it favorably under this body of case law.
E. Penalty Implications of the Economic Substance Doctrine
The penalty implications of the IRS's choice of legal theory are significant and must be considered in developing PPC's defense strategy.
IRC § 6662(b)(6) imposes a 20% penalty on any underpayment of tax attributable to any disallowance of claimed tax benefits by reason of a transaction lacking economic substance (as defined in § 7701(o)) or failing to meet the requirements of any similar rule of law. This penalty is a strict-liability penalty: under IRC § 6662(i), the reasonable-cause exception of § 6664(c) does not apply to any portion of an underpayment attributable to a transaction lacking economic substance. Moreover, under § 6662(i)(2), if the taxpayer did not adequately disclose the relevant facts affecting the tax treatment of the transaction in the return or in a statement attached to the return, the penalty is increased to 40%.
This strict-liability penalty regime stands in sharp contrast to the penalty framework applicable to transfer pricing adjustments under IRC § 6662(e), which imposes a 20% penalty for substantial valuation misstatements (increasing to 40% for gross valuation misstatements) but allows a reasonable-cause defense under IRC § 6662(e)(3)(B) where the taxpayer demonstrates that it acted in good faith and maintained contemporaneous documentation establishing that its transfer pricing satisfied the arm's-length standard. PPC has prepared and maintained contemporaneous transfer pricing documentation for the CSA and the legacy IP royalty arrangement, which would support a reasonable-cause defense under § 6662(e)(3)(B) if the IRS's challenge is framed exclusively as a § 482 arm's-length pricing adjustment.
The strategic significance of this distinction cannot be overstated. If the IRS reclassifies its challenge from a § 482 transfer pricing adjustment to a § 7701(o) economic substance challenge — or advances both theories simultaneously — PPC would lose the benefit of its contemporaneous documentation defense as to any underpayment attributable to the economic substance challenge. The strict-liability penalty under § 6662(b)(6) would apply regardless of whether PPC acted in good faith and maintained robust documentation. This makes it critical to defeat any economic substance challenge entirely, rather than relying on a fall-back defense of reasonable cause and contemporaneous documentation.
We should anticipate that the IRS may pursue a dual strategy: asserting both a § 482 arm's-length pricing adjustment and, in the alternative, an economic substance challenge under § 7701(o). This approach would maximize the IRS's leverage by creating penalty exposure under § 6662(b)(6) even if the § 482 pricing adjustment is modest. The involvement of IRS Chief Counsel Attorney-Advisor Franklin Rosario in the examination suggests that the IRS may already be developing legal theories beyond the standard § 482 adjustment.
Our defense strategy should therefore address both levels of the IRS's anticipated challenge: (1) demonstrate that PBI has economic substance and that § 7701(o) does not apply; and (2) demonstrate that the intercompany pricing (CSA ratios and royalty rates) satisfies the arm's-length standard under § 482. The substance analysis informs and strengthens both defenses.
IV. The DEMPE Framework Under OECD Transfer Pricing Guidelines
A. Overview of DEMPE
The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as subsequently updated in 2022) provide the internationally recognized framework for the analysis of transfer pricing in controlled transactions. Chapter VI of the OECD Guidelines addresses "Special Considerations for Intangibles" and establishes the DEMPE framework at paragraphs 6.32 through 6.71.
DEMPE is an acronym for the five categories of functions relevant to determining which entity in a multinational group should be entitled to returns from intangible property:
D — Development: Activities related to the creation and advancement of intangible property, including research and development, clinical trials, formulation, process development, and design.
E — Enhancement: Activities that improve, expand, or augment the value of existing intangible property, including line extensions, new indications or formulations, additional clinical or technical data, and improvements to manufacturing processes.
M — Maintenance: Activities that preserve and sustain the value of intangible property over time, including quality control, regulatory compliance, pharmacovigilance and adverse-event reporting, patent prosecution and renewal, and ongoing quality assurance.
P — Protection: Activities that defend intangible property rights against infringement, misappropriation, or dilution, including patent enforcement, trademark defense, trade-secret protection, anti-counterfeiting measures, and related litigation.
E — Exploitation: Activities related to the commercialization and monetization of intangible property, including marketing, sales, pricing, distribution, market access, customer relationships, and related commercial operations.
The DEMPE framework embodies a core principle of the OECD Guidelines: legal ownership of intangible property, standing alone, does not entitle an entity to the returns generated by that property. Rather, the returns from intangible property should be attributed to the entity or entities that perform, or control the performance of, important DEMPE functions, use important assets in connection with those functions, and assume and manage economically significant risks associated with those functions. An entity that holds legal title to intangible property but does not perform — or control the performance of — important DEMPE functions, does not use important assets, and does not assume and manage economically significant risks, is entitled to no more than a risk-free return (or a return appropriate to a funding-only role, adjusted for the risk of the funding activity).
This principle has significant implications for multinational pharmaceutical groups like PPC. In the pharmaceutical industry, the value of intangible property — patents, clinical data, marketing authorizations, know-how, and brand value — is the primary driver of profitability. The DEMPE framework requires that the returns from pharmaceutical IP be attributed to the entity or entities that contribute to the creation, maintenance, and exploitation of that value through their functional activities, risk assumption, and asset deployment. A foreign subsidiary that holds IP rights but serves merely as a "brass plate" entity without substantive operations would not, under the DEMPE framework, be entitled to the returns associated with that IP.
While the OECD Transfer Pricing Guidelines are not binding U.S. law, they are treated as persuasive authority by the IRS and by U.S. courts, particularly in transfer pricing disputes. As discussed in Section III.D above, both the Tax Court and the federal circuit courts have referenced the OECD Guidelines in analyzing transfer pricing issues. The IRS itself relies on OECD DEMPE concepts in its audit practice, and the examination team in this matter has referenced DEMPE in its initial IDRs. Accordingly, the DEMPE framework provides a useful analytical structure for evaluating and defending PBI's substance, even though the U.S. transfer pricing regulations do not expressly adopt the DEMPE terminology.
B. Application of Each DEMPE Function
1. Development. Definition. Under the OECD Guidelines, "Development" encompasses the research and development activities that lead to the creation of intangible property. In the pharmaceutical context, this includes basic research, drug discovery, preclinical studies, clinical trials (Phase I through Phase III), formulation development, process development, and related regulatory activities necessary to obtain marketing authorization.
PPC's Role. PPC conducts the substantial majority of R&D activities from its headquarters in Princeton Junction, New Jersey. PPC's R&D function includes approximately 2,800 scientists, researchers, and clinical development professionals. PPC's laboratories, clinical trial management operations, and core drug discovery programs are located primarily in the United States. PPC is the primary executor of the R&D activities funded through the CSA cost pool.
PBI's Role. PBI co-funds the R&D activities through its cost-sharing payments under the CSA, contributing 38.2% to 42.7% of the total annual R&D cost pool during the examination years ($186.15 million to $255.52 million annually). PBI's co-funding represents a substantial financial commitment to the Development function. In addition to funding, PBI provides input on non-Americas regulatory requirements that influence development priorities. PBI's regulatory affairs team in Dublin monitors evolving regulatory standards in the non-Americas territory (including EMA scientific guidelines, HPRA requirements, and requirements of other national regulatory agencies) and communicates those requirements to PPC's R&D team so that development programs are designed to support regulatory filings in both the Americas and non-Americas territories. PBI also employs regulatory affairs personnel who contribute to regulatory strategy for non-Americas-specific filings, including the preparation and submission of marketing authorization applications tailored to the regulatory requirements of individual country markets.
Key Question. Whether co-funding R&D activities plus regulatory input constitutes sufficient participation in the "Development" function, or whether the actual physical conduct of bench-level R&D is required.
Analysis. Under the OECD Guidelines (paragraphs 6.56–6.58), an entity can meaningfully participate in the Development function through a combination of control over and financing of development activities, coupled with bearing development risk. The Guidelines do not require that an entity physically conduct laboratory research in order to participate in the Development function; rather, the entity must exercise control over the development process, contribute to the development through its financial resources and functional inputs, and bear the economic risk of unsuccessful development outcomes. PBI satisfies these requirements: PBI commits substantial capital to the R&D cost pool through its cost-sharing payments; PBI provides functional input through its regulatory affairs team; and PBI bears the economic risk that R&D investments may not yield commercially viable products in its territory (including the risk of clinical trial failure, regulatory rejection, and market non-acceptance). Under the CSA, PBI has a contractual right to the results of the co-funded R&D for its territory and bears the financial consequences of R&D success or failure. The Ninth Circuit's decision in Altera affirms the validity of cost-sharing arrangements that allocate development costs and rights on this basis. PBI's participation in the Development function is therefore assessed as moderate-to-strong.
2. Enhancement. Definition. "Enhancement" encompasses activities that improve, expand, or augment the value of existing intangible property. In the pharmaceutical context, this includes line extensions (new dosage forms, new routes of administration), new indication studies, reformulations, post-marketing clinical studies, and the generation of additional clinical data that supports expanded use or market access.
PPC's Role. PPC's U.S.-based R&D team leads the majority of enhancement activities, including the design and execution of new indication studies and the development of new formulations.
PBI's Role. PBI makes meaningful contributions to the Enhancement function in several ways. PBI initiates and funds non-Americas-specific clinical studies, including studies required by non-Americas regulatory agencies as conditions of marketing authorization or post-marketing commitments. PBI contributes to post-marketing studies that generate real-world evidence supporting the continued use and expanded access of PPC's products in non-Americas markets. PBI's regulatory affairs and medical affairs teams provide market intelligence that informs enhancement decisions, including feedback from non-Americas healthcare professionals, payers, and regulatory agencies regarding unmet clinical needs, competitive dynamics, and regulatory expectations. PBI's cumulative regulatory expenditure of €47.2 million over the 2017–2020 period reflects the costs associated with regulatory submissions, marketing authorization applications, and post-marketing commitments, many of which involve activities that enhance the value of the underlying intangible property by expanding its geographic footprint, securing new indications, or generating additional clinical evidence. PBI's participation in the Enhancement function is assessed as moderate.
3. Maintenance. Definition. "Maintenance" encompasses activities that preserve the value of intangible property over time. In the pharmaceutical context, this includes regulatory compliance (maintaining marketing authorizations, filing variations and renewals, responding to regulatory inquiries), pharmacovigilance (adverse event monitoring and reporting), quality control, and patent prosecution and renewal.
PPC's Role. PPC manages the global patent portfolio and conducts U.S.-focused pharmacovigilance and quality-control activities.
PBI's Role. PBI performs extensive Maintenance functions for the non-Americas territory. PBI manages regulatory compliance across 68 country markets, which involves the ongoing maintenance of marketing authorizations (including periodic renewal applications, Type IA, Type IB, and Type II variations, and responses to regulatory agency queries), compliance with labeling requirements, and monitoring of evolving regulatory standards. PBI manages relationships with non-Americas regulatory agencies, including direct engagement with the EMA, the HPRA, the MHRA, and national regulatory agencies throughout Europe, Asia-Pacific, the Middle East, and Africa. PBI maintains local pharmacovigilance operations, including adverse event monitoring, signal detection, periodic safety update report preparation, and risk management plan implementation for the non-Americas territory. PBI employs dedicated medical-affairs staff in Dublin who manage medical information inquiries, medical education programs, and advisory board relationships with non-Americas key opinion leaders.
The evidence supporting PBI's Maintenance function includes: PBI's regulatory submission expenditures (€47.2 million cumulative, a portion of which relates to maintenance activities); PBI's medical-affairs headcount; PBI's pharmacovigilance infrastructure; and the documented compliance activities across 68 country markets. PBI's participation in the Maintenance function is assessed as strong.
4. Protection. Definition. "Protection" encompasses activities that defend intangible property rights against infringement, misappropriation, or dilution. In the pharmaceutical context, this includes patent enforcement and defense, trademark registration and defense, trade-secret protection, anti-counterfeiting measures, and related litigation and enforcement activities.
PPC's Role. PPC manages global patent prosecution (preparation and filing of patent applications) and leads primary patent litigation management, including Hatch-Waxman proceedings in the United States and major cross-border patent disputes.
PBI's Role. PBI manages local IP enforcement in non-Americas territories, including the coordination of patent enforcement actions in European and other jurisdictions, coordination with local external counsel on trademark and patent matters, and engagement in anti-counterfeiting measures in non-Americas markets. PBI's in-house legal team, supported by external local counsel, monitors for potential IP infringements in PBI's territory and takes enforcement action where necessary. PBI also manages trademark registrations and renewals in non-Americas jurisdictions, ensuring that the PPC product trademarks are protected across PBI's distribution markets.
While PPC maintains primary responsibility for global patent prosecution and major litigation, PBI's contributions to the Protection function in its territory are meaningful. PBI exercises authority over local enforcement decisions, selects and manages local counsel, and bears the costs of local IP enforcement. PBI's participation in the Protection function is assessed as moderate.
5. Exploitation. Definition. "Exploitation" encompasses the commercialization and monetization of intangible property — the activities through which IP is converted into revenue. In the pharmaceutical context, this includes marketing, sales, pricing, market access, distribution, customer (healthcare provider and payer) relationships, and supply-chain management.
PBI's Role. Exploitation is PBI's strongest DEMPE function. PBI serves as the commercial principal for the non-Americas territory and performs the full range of Exploitation functions:
• Independent Pricing Authority: PBI makes independent pricing decisions across 68 non-Americas country markets. Pricing decisions are made by PBI's commercial strategy team in Dublin, informed by market-specific analyses of competitive dynamics, payer requirements, reimbursement frameworks, and regulatory constraints. PBI's pricing committee meets regularly and documents its pricing decisions and the rationale therefor.
• Distribution Partner Management: PBI selects and manages distribution partners in markets where PBI does not maintain a direct sales presence. PBI negotiates distribution agreements, monitors distributor performance, and makes decisions regarding distributor appointment, retention, and termination.
• Market Entry Strategy: PBI determines market entry strategy and timing for new products and new geographic markets within its territory. PBI evaluates market opportunity, regulatory pathway, competitive landscape, and commercial feasibility for each potential market en

RESEARCH MEMORANDUM PRIVILEGED & CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

MATTER NO.: 1018-00009

Record

Parties

Dates

Amounts